Metilene Blue and Alzheimer

Methylene blue has been investigated as a potential treatment for neurodegenerative diseases, including Alzheimer’s disease, due to its neuroprotective, antioxidant properties and its ability to influence the mechanisms underlying the disease.

How Methylene Blue Works in Alzheimer’s

1. Inhibition of Tau Protein Aggregation:
   • In Alzheimer’s, abnormal tau proteins form tangles (neurofibrillary tangles) that damage brain cells.
   • Methylene blue has shown the ability to inhibit the aggregation of tau proteins and even dissolve existing tangles, helping to protect neurons.
2. Reduction of Oxidative Stress:
   • It acts as an antioxidant, neutralizing free radicals that contribute to cell damage and cognitive decline in Alzheimer’s disease.
3. Improvement in Mitochondrial Function:
   • Methylene blue can act as an electron carrier in mitochondria, enhancing energy (ATP) production. This is critical because brain cells in Alzheimer’s often suffer from mitochondrial dysfunction.
4. Neuroprotection and Synaptic Plasticity:
   • It supports the ability of neurons to form new connections (synaptic plasticity), which is essential for learning and memory.

Research Evidence

A stabilized form of methylene blue, known as LMTM (Leuco-Methylthioninium Mesylate), has been tested in human clinical trials. Some studies reported positive effects in slowing cognitive decline in patients with mild to moderate Alzheimer’s.

Preclinical Studies: Animal models of Alzheimer’s have shown improvements in memory and reductions in Alzheimer’s-related pathology, such as tau tangles, with methylene blue treatment.

Clinical Trials:

A stabilized form of methylene blue, known as LMTM (Leuco-Methylthioninium Mesylate), has been tested in human clinical trials. Some studies reported positive effects in slowing cognitive decline in patients with mild to moderate Alzheimer’s.